clinical trial · NCT07721025
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
Friedreich AtaxiaCardiomyopathy, SecondaryLX2006Usual Care
brief summary
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
started
Jun 25, 2026
primary completion
Jun 1, 2032
completion
Jun 1, 2032
last updated
Sep 2, 2026
official title
A Phase 2, Multicenter, Open-label, Randomized, Controlled Study of LX2006 Gene Therapy in Participants With Friedreich Ataxia Cardiomyopathy (SUNRISE-FA 2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol